Trial intelligence / Profile preview

TNFalpha Blocking in Spondylarthropathies

NCT00133315Phase 4Completed

Sponsor: Copenhagen University Hospital - Hvidovre
Start: Sep 2004
Modality: Monoclonal Antibodies, Fc-Fusion Proteins
Countries: 1

Overview

Phase 4, open-label, single-arm trial of infliximab, etanercept and adalimumab in Spondyloarthritis (SpA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), sponsored by Copenhagen University Hospital - Hvidovre. Started Sep 2004; status: completed.

Drugs

infliximabetanerceptadalimumab

Conditions

Spondyloarthritis (SpA)ankylosing spondylitis (AS)psoriatic arthritis (PsA)

Beyond the preview

Go deeper on NCT00133315.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00133315.